Session 4: New Evidence-Based Clinical Prac ce Guidelines B: Management of Osteoporosis in Post-Menopausal Women 4:15pm - 5:15pm
|
|
- Jonathan Davidson
- 5 years ago
- Views:
Transcription
1 January 20-22, 2012 Des Moines Marrio, 700 Grand Avenue, Des Moines, IA Session 4: New Evidence-Based Clinical Prac ce Guidelines B: Management of Osteoporosis in Post-Menopausal Women 4:15pm - 5:15pm ACPE UAN L01-P Ac vity Type: Applica on-based 0.1 CEU/1.0 Hr Program Objec ves for Pharmacists: Upon comple on of this CPE ac vity par cipants should be able to: 1. Iden fy which pa ents will benefit from addi onal calcium supplementa on 2. Recommend a dose of calcium for those pa ents that need supplementa on 3. Recall recommenda ons for vitamin D supplementa on 4. Iden fy common and serious adverse effects associated with long term use of bisphosphonates 5. Recognize those pa ents that would benefit from therapy with recombinant parathyroid hormone therapy Speaker: Ann M. Philbrick, PharmD, BCPS, is an Assistant Professor in the College of Pharmacy at the University of Minnesota and a Clinical Pharmacist at the University of Minnesota Veterinary Medical Center. She is on the faculty of St. Joseph s Family Medicine Residency Program and maintains her pharmacy prac ce at Bethesda Family Medicine Clinic. She is a 2006 graduate of the University of Nebraska Medical Center and completed the combined PGY1 and PGY2 Ambulatory Care Residency at the University of Iowa Hospitals and Clinics in Dr. Philbrick s prac ce and scholarship interests revolve around the role of a clinical pharmacist within a family medicine clinic. Speaker Disclosure: Ann Philbrick does not report any actual or poten al conflicts of interest in rela on to this CPE ac vity. Off-label use of medica ons will not be discussed during this presenta on.
2 Management of Osteoporosis in Post-Menopausal Women Ann M. Philbrick, Pharm.D., BCPS Assistant Professor University of Minnesota College of Pharmacy Faculty Disclosure Dr. Philbrick reports she has no actual or potential conflicts of interest associated with this presentation. Dr. Philbrick has indicated that off-label use of medication will not be discussed during this presentation. Learning Objectives Upon completion of this activity pharmacists (or pharmacy technicians) will be able to: Identify which patients will benefit from additional calcium supplementation. Recommend a dose of calcium for those patients that need supplementation. Recall recommendations for vitamin D supplementation. Identify common and serious adverse effects associated with long term use of bisphosphonates. Recognize those patients that would benefit from therapy with recombinant parathyroid hormone therapy. Pre-Assessment Questions 1. Which of the following defines osteoporosis? A. T-Score -1 to -2.5 B. T-Score < -2.5 C. Z-Score -1 to -2.5 D. Z-Score < What is the drug of choice for treatment of osteoporosis? A. Bisphosphonate B. Teriparatide C. Calcitonin D. All of the Above Pre-Assessment Questions 3. Based on recent studies, how much elemental calcium does a postmenopausal woman, who is getting 750mg of dietary calcium need? A. None B. 250mg C. 450mg D. 1200mg Osteoporosis A Definition Low bone mass Deterioration of the bone tissue / architecture Compromised bone strength Increased risk of fracture Diagnosed by: BMD -2.5 SD at the hip or spine 1
3 Epidemiology 10 million Americans with Osteoporosis 33.6 million have low bone density* 1 in 2 Caucasian women will experience an osteoporotic fracture in their lifetime Pathophysiology BONE RESORPTION BONE FORMATION Pathophysiology Patient Case Ilene Dover (I.D.) 65 y.o. postmenopausal caucasian woman PMHx: hypertension and asthma. Meds: metoprolol, aspirin, fluticasone and albuterol inhalers SHX: Retired. Married. Tobacco: none. Alcohol: 1 glass of wine daily. Exercise: rides bicycle 4 days per week. ROS : chronic, mild back pain over past 2 years. Vitals: Ht: 66 inches (168 cm) BMI = 24.3 Wt: 150 lbs (68.2 kg) BP 138/60 Family Hx: mom had hip fracture at age 72 Fracture Hx: patient slipped on the ice and fracture wrist 2 years ago. Is I.D. at risk for a fracture? How to Measure Bone Density Central DEXA: images the hip and spine. Used to define osteoporosis, predict risk of fracture, and monitor treatment. Peripheral DEXA: images the forearm, finger, or heel. Predicts fracture risk but not useful for monitoring. CT and Ultrasound based bone density measures are not used at this time. 2
4 What is a DEXA Scan? DEXA is Dual-energy x-ray absorptiometry Values: T-score Compares bone density to young adults of the same gender. Z-score Compares bone density to age-matched adults of the same gender. Results expressed in standard deviation from the mean. A single standard deviation decline in DXA score predicts a 2.6 relative risk increase in hip fracture. Who Needs a DEXA Scan? Women age 65 and older and men age 70 and older, regardless of clinical risk factors Women in the menopausal transition if there is a specific risk factor associated with increased fracture risk such as low body weight, prior low-trauma fracture, or high risk medication. Younger postmenopausal women and men age about whom you have concern based on their clinical risk factor profile Adults who have a fracture after age 50 Who Needs a DEXA Scan? Adults with a condition (e.g., rheumatoid arthritis) or taking a medication (eg glucocorticoids, 5 mg/day for 3 months) associated with low bone mass or bone loss Anyone being considered for pharmacologic therapy for osteoporosis Anyone being treated for osteoporosis, to monitor treatment effect Anyone not receiving therapy in whom evidence of bone loss would lead to treatment Postmenopausal women discontinuing estrogen should be considered for bone density testing. Does I.D. Need a DEXA Scan? YES Why: female & over age 65 year Her Results: -2.0 at the left femoral neck She does NOT have osteoporosis Influence of Age & T-Score on Fracture Rates Risk of Fracture Osteoporos Int. 2006:17:565 NEJM. 2008;358:
5 FRAX Score Fracture Risk Assessment Tool WHO web based fracture risk tool. Input individual Risk Factors for fracture. Gives 10 year fracture rate for both major osteoporotic fractures and hip fractures. High risk is defined as Risk of any fracture > 20% Risk of hip fracture > 3% Key point: FRAX helps us to turn relative risk into absolute risk for individual patients FRAX Score for I.D. Available: FRAX Score for I.D. Question: What is I.D. s Risk? HIGH Risk for: Major Osteoporotic Fracture Hip Fracture I.D. should be treated as if she has osteoporosis Does I.D. Need Calcium Supplementation? Adequate Calcium Intake Women older than 50 years: 1200 mg elemental calcium / day National Osteoporosis Foundation 4
6 Daily Calcium Estimation STEP 1 Product Servings/Day X Estimated elemental = Calcium (mg) calcium/serving (mg) Milk (8oz.) X 300 = Yogurt (6 oz) X 300 = Cheese (1 oz.) X 200 = Fortified foods/juice X = STEP 2: + 250mg from non-dairy sources 250mg TOTAL DAILY CALCIUM INTAKE Daily Calcium Estimation for I.D. STEP 1 Product Servings/Day X Estimated elemental = Calcium (mg) calcium/serving (mg) Milk (8oz.) 1 X 300 = 300 Yogurt (6 oz) 0 X 300 = 0 Cheese (1 oz.) 1 X 200 = 200 Fortified foods/juice 0 X = 0 STEP 2: + 250mg from non-dairy sources 250mg TOTAL DAILY CALCIUM INTAKE 750mg WHI Calcium & CV Risk Re-analysis of Women s Health Initiative CaD Study Original: randomized to receive calcium carbonate 500 mg with vitamin D 200 IU BID or placebo Problem: high personal use of calcium clouded the results New analysis: stratified into two groups personal vs. nonpersonal use of calcium (± vitamin D) WHI Calcium & CV Risk BMJ. 2011;342:2040 BMJ. 2011;342:2040 WHI Calcium & CV Risk Does I.D. Need Calcium Supplementation? Approximate dietary intake: 750mg At this time, no Could recommend more dietary intake Conclusion When persons with no personal calcium supplementation were randomized to receive calcium, they had a high incidence of MI & stroke BMJ. 2011;342:2040 5
7 Does I.D. Need Vitamin D Supplementation? Screening for Vitamin D Deficiency Screening should be completed in persons at risk for deficiency Rickets Older adults with a hx of falls Osteomalacia Older adults with a hx of nontraumatic fractures Osteoporosis CKD Granuloma-forming disorders Malaborption disorders On certain medications: Hyperparathyroidism Anti-seizure African American person Glucocorticoids Anti-retrovirals Hispanic persons Antifungals Pregnant/Lactating Women Cholestyramine Obese persons J Clin Endocrinol Metab. 2011:96: hydroxyvitamin D [25(OH)D] Levels Normal: > 30 ng/ml Insufficiency: ng/ml Deficiency: < 20 ng/ml Vitamin D Intake Adequate daily intake IU / day Treatment on deficiency 50,000 IU once weekly or 6,000 IU daily for 8 weeks Maintenance dose: IU daily J Clin Endocrinol Metab. 2011:96:1911 J Clin Endocrinol Metab. 2011:96:1911 Vitamin D 2 vs D 3 Vitamin D 2 Ergocalciferol Body gets from the food Exception: oil-rich fish Converted to D 3 in the body Vitamin D 3 Cholecalciferol Body gets from sun Readily used by the body Other Uses for Vitamin D Should be prescribed for: Fall prevention Should not be prescribed for: Cardiovascular disease prevention Quality of Life Improvement Guidelines Give No Preference to Either Supplement J Clin Endocrinol Metab. 2011:96:1911 J Clin Endocrinol Metab. 2011:96:1911 6
8 Does I.D. Need Vitamin D Supplementation? 25(OH)D Level: 31.2 ng/ml Yes IU / day D 2 or D 3 What Pharmacotherapy Should I.D. Receive? Pharmacotherapy Indications Men or women over 50 with hip or vertebral (clinical or morphometric) fracture Prior fractures associated with low bone mass (T-score -1.0 to -2.5) T-score -2.5 or less Low bone mass and glucocorticoid use or need for prolonged immobilization Low bone mass and 10-yr hip fracture rate >3% or 10-yr major osteoporotic fracture risk > 20% based on WHO algorithm Pharmacotherapy Options Bisphonphonates: drugs of choice Parathyroid hormone Calcitonin Bisphosphonates Work by: inhibiting osteoclastic activity Products: Alendronate (Fosamax ) Oral: daily, weekly Risedronate (Actonel, Atelvia ) Oral: daily, weekly, monthly Ibandronate (Boniva ) Oral: daily, monthly Every 3 month infusion Zolendronic Acid (ZA) (Reclast ) Yearly infusion Bisphosphonates Adverse Effects: Gastrointestinal effects Difficulty swallowing, esophageal inflammation, gastric ulcer Osteonecrosis of the jaw Atrial fibrillation with ZA administration Atypical fractures Subtrochanteric & diaphyseal femur fractures Not yet known if related, but most cases have appeared in patients on bisphosphonates Esophageal cancer? FDA statement: benefits of bisphosphonates outweigh the small (possible) risk of cancer 7
9 Post-Menopausal Osteoporosis ZA vs. placebo in post-menopausal women with osteoporosis Infused at baseline, 12 & 24 months Also received daily calcium/d supplementation Primary Outcome: new vertebral fractures and hip fractures Recurrent Fractures Zolendronic acid (ZA) vs. placebo following surgical repair of hip fracture Primary outcome: New clinical fracture ZA administered within 90 days of fracture Every 12 months thereafter All subjects received loading dose of Vitamin D2 or D3 if deficient All subjects received oral calcium/d vitamin supplementation NEJM; 2007;356:1809 NEJM. 2007;357:1799. Recurrent Fractures Teriparatide (Forteo ) Parathyroid hormone Anabolic effect on bone Given 20 mcg SQ daily Long term safety (>2 years) unknown Increase risk of osteosarcoma in rats One case in humans NEJM. 2007;357:1799. Postmenopausal Women Randomized, double-blind, placebo-controlled trial Teriparatide 20mcg, 40mcg or placebo for 24 months Postmenopausal Women NEJM. 2001;344:1434 NEJM. 2001;344:1434 8
10 Teriparatide, Alendronate or Both in Post-Menopausal Women Randomized, controlled trial Not placebo controlled Alendronate 10mg daily (group 1), teriparatide 40mcg daily (group 2) or both (group 3) Calcitonin Nasal spray used daily Indicated for post-menopausal osteoporosis May reduce pain associated with fractures J Clin Endocrinol Metab. 2010;95:1838 Postmenopausal Osteoporosis Randomized, double-blind, placebo controlled trial Intranasal calcium daily, TIW or placebo Summary I.D. Needed a DEXA scan based on age, menopausal status DEXA 2.0 low bone density FRAX Scores 32% 10-year risk of major osteoporotic fracture 4.3% 10-year risk of hip fracture Does not need calcium supplementation Does need vitamin D supplementation Would suggest bisphosphonate as first line therapy Not osteoporotic, but is warranted based on high FRAX score CalcifTissue Int. 1996:59:6. Summary BMD does not necessarily confer with fracture risk led to the development of the FRAX Score Current medical theory is straying away from calcium supplementation; encouraging increased dietary intake Vitamin D supplementation Recommended for all at 800 to 1000 IU daily 50,000 IU once weekly for 8 weeks Drug therapy is recommended for T-Score <-2.5, 10-year major osteoporotic fracture risk > 20% or hip fracture risk > 3% Bisphosphonates remain the drug of choice but teriparatide and calcitonin show promise Post-Assessment Questions 1. Which of the following defines osteoporosis? A. T-Score -1 to -2.5 B. T-Score < -2.5 C. Z-Score -1 to -2.5 D. Z-Score < What is the drug of choice for treatment of osteoporosis? A. Bisphosphonate B. Teriparatide C. Calcitonin D. All of the Above 9
11 Post-Assessment Questions 3. Based on recent studies, how much elemental calcium does a postmenopausal woman, who is getting 750mg of dietary calcium need? A. None B. 250mg C. 450mg D. 1200mg Continuing Pharmacy Education Go to click on My Portfolio Scroll down to Take Exam Enter Access Code: (case sensitive) Pharmacists - Technicians - 10
12 2012 Educational Expo Management of Osteoporosis in Postmenopausal Women Ann Philbrick, PharmD, BCPS Post Assessment Questions 1. Which of the following defines osteoporosis? A. T Score 1 to 2.5 B. T Score < 2.5 C. Z Score 1 to 2.5 D. Z Score < What is the drug of choice for treatment of osteoporosis? A. Bisphosphonate B. Teriparatide C. Calcitonin D. All of the Above 3. Based on recent studies, how much elemental calcium does a postmenopausal woman, who is getting 750mg of dietary calcium need? A. None B. 250mg C. 450mg D. 1200mg
13 New Evidence-Based Clinical Practice Guidelines: Management of Osteoporosis in Post-Menopausal Women I.D. 65 y.o. postmenopausal caucasian woman PMHx: hypertension and asthma. Meds: metoprolol, aspirin, fluticasone and albuterol inhalers SHX: Retired. Married. Tobacco: none. Alcohol: 1 glass of wine daily. Exercise: rides bicycle 4 days per week. ROS : chronic, mild back pain over past 2 years. Vitals: Ht: 66 inches (168 cm) Wt: 150 lbs (68.2 kg) BP 138/60 Family Hx: mom had hip fracture at age 72 Fracture Hx: patient slipped on the ice and fracture wrist 2 years ago. T-score at left femoral neck: -2.0 FRAX Score Major Osteoporotic: 32% Hip Fracture: 4.3% Estimated dietary calcium intake: 750mg (Assessment) Patient problems: System problems: Intervention: (Plan)
John J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationOsteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon
Osteoporosis in Men Wendy Rosenthal PharmD This program has been brought to you by PharmCon Osteoporosis in Men Speaker: Dr. Wendy Rosenthal, President of MedOutcomes, will be the presenter for this webcast.
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationBone Health for Women: Current Research, Initiatives and Recommendations
Page 1 BONE HEALTH FOR WOMEN: CURRENT RESEARCH, INITIATIVES AND RECOMMENDATIONS Dr. Melissa Kagarise This program has been brought to you by PharmCon PharmCon is accredited by the Accreditation Council
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationKeeping old bones from breaking: The diagnosis, prevention, and treatment of osteoporosis
Keeping old bones from breaking: The diagnosis, prevention, and treatment of osteoporosis Balanced data about medications www.rxfacts.org Copyright 2010 by The Alosa Foundation. All rights reserved. www.rxfacts.org
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationOsteoporosis. Skeletal System
Osteoporosis Introduction Osteoporosis is a very common bone disease that causes bone to become weak. Bone weakness can lead to fractures of the spine, hip, and wrist from simple falls or even a sneeze
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationOsteoporosis and Lupus. Andrew Ruthberg, MD University Rheumatologists
Osteoporosis and Lupus Andrew Ruthberg, MD University Rheumatologists 1 Forget the medical terminology (osteoporosis, osteopenia, low bone mass, DEXA, DXA, T score etc) The bottom line is that you don
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationFocusing on the Patient: Diagnosis and Management of Osteoporosis
Focusing on the Patient: Diagnosis and Management of Osteoporosis Learning Objectives After participating in this educational activity, participants should be able to: 1. Apply updated guidelines to assess
More informationOsteoporosis Update. Case 2. Case 1: Monday morning, 8:15
Osteoporosis Update Laura E. Ryan, MD Assistant Director for Special Programs Center for Women s Health Clinical Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationPrevalence of Osteoporosis 5/3/2017. Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist
Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist Prevalence of Osteoporosis 1.5 million fractures annually in the U.S. Overall lifetime risk for an osteoporotic fracture is about
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationOsteoporosis. Definition
Osteoporosis Definition Osteoporosis causes bones to become weak and brittle so brittle that a fall or even mild stresses like bending over or coughing can cause a fracture. Osteoporosis-related fractures
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationBisphosphonates. Making intelligent drug choices
Making intelligent drug choices Bisphosphonates are a first choice for treating osteoporosis, according to Kedrin E. Van Steenwyk, DO, an obstetrician/gynecologist at Sycamore Women s Center, Miamisburg,
More informationTalking to patients with osteoporosis about initiating therapy
Talking to patients with osteoporosis about initiating therapy Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationShon E. Meek, M.D., Ph.D. Assistant Professor of Medicine
Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine meek.shon@mayo.edu 2016 MFMER 3561772-1 Update on Vitamin D Shon Meek MD, PhD 20 th Annual Endocrine Update January 30-Feb 3, 2017 Disclosure Relevant
More informationMajor Recommendations Recommendations apply to postmenopausal women and men age 50 and older.
Clinical Practice Guideline Effective August 2007 (Revised 10/09) This guideline is based upon the guideline developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration
More informationMAKE NO BONES ABOUT IT: UNDERSTANDING THE PHARMACIST S ROLE IN OSTEOPOROSIS MANAGEMENT. Jill Hiers, Pharm.D., BCPS
MAKE NO BONES ABOUT IT: UNDERSTANDING THE PHARMACIST S ROLE IN OSTEOPOROSIS MANAGEMENT Jill Hiers, Pharm.D., BCPS Outline Definition of osteoporosis/osteopenia Disease prevalence/burden Risk Factors AACE
More informationPage 1
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationSummary of the risk management plan by product
Summary of the risk management plan by product 1 Elements for summary tables in the EPAR 1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Important potential risks
More informationObjectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.
Objectives Discuss bone health and the consequences of osteoporosis on patients medical and disability status. Discuss the pathophysiology of osteoporosis and major risk factors. Assess the major diagnostic
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationOsteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationOSTEOPOROSIS MEDICINES
Bone Basics 2010. NOF. All rights reserved. National Osteoporosis Foundation 1150 17th Street, NW, Suite 850 Washington, DC 20036 (800) 223-9994 www.nof.org OSTEOPOROSIS MEDICINES Although there is no
More informationTymlos (abaloparatide)
Tymlos (abaloparatide) Policy Number: 5.01.638 Last Review: 11/2018 Origination: 10/2017 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Tymlos
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationDISCLAIMER DO NOT DISTRIBUTE
DISCLAIMER The information contained in this presentation is not intended as a substitute for professional medical advice, diagnosis, or treatment. It is provided for educational purposes only. You assume
More informationOsteoporosis is defined as a systemic skeletal disease characterized by low
Reviews preventing and treating osteoporosis Reviews Benefits and risks of preventing and treating osteoporosis American Pharmacists Association Osteoporosis is defined as a systemic skeletal disease characterized
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationBone Health in Celiac Disease. Partha S. Sinha MD, PhD October 29 th, 2017
Bone Health in Celiac Disease Partha S. Sinha MD, PhD October 29 th, 2017 No Disclosures Objectives Recognize the mechanisms by which celiac disease can affect bone health Review what diagnostic tests
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationPrevention and Treatment of OSTEOPOROSIS 骨質疏鬆的預防與治療
Prevention and Treatment of OSTEOPOROSIS 骨質疏鬆的預防與治療 Gwo Jaw Wang, M.D. 王國照教授 University of Virginia (U.S.A.) & National Cheng Kung University (Taiwan) Learning Objectives Pathophysiology of osteoporosis
More informationClinical Practice. Presented by: Internist, Endocrinologist
Clinical Practice Management of Osteoporosis Presented by: SaeedBehradmanesh, h MD Internist, Endocrinologist Iran, Isfahan, Feb. 2017 Definition: A disease characterized by low bone mass and microarchitectural
More information11/4/2018. Osteoporosis Update. ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East. No disclosures.
Osteoporosis Update ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East No disclosures. 1 Goals Review screening recommendations and workup of secondary causes
More informationManagement of Osteoporosis Clinical Practice Guideline September 2013
Management of Osteoporosis Clinical Practice Guideline September 2013 MedStar Health and MedStar Family Choice accept and endorse the clinical guidelines set forth by the National Osteoporosis Foundation
More informationPage 1. Current and Emerging Strategies for Osteoporosis. Osteoporosis Warm-Up: Which of the Following is True?
Current and Emerging Strategies for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis Warm-Up:
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationOsteoporosis for the PCP and consultant COPYRIGHT. Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center
Osteoporosis for the PCP and consultant Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center Beth Israel Deaconess Medical Center Potential conflicts of interest None GOALS When to screen/treat?
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationMarcy B. Bolster, MD Associate Professor of Medicine Division of Rheumatology Endocrine Associates Massachusetts General Hospital
Marcy B. Bolster, MD Associate Professor of Medicine Division of Rheumatology Endocrine Associates Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationPathway from Fracture or Risk Factor to Treatment
Appendix 6A - Guidance on Diagnosis and Management of Osteoporosis Pathway from Fracture or Risk Factor to Treatment Fragility Fracture = fracture sustained from a low energy fall from standing height
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationFracture=Bone Attack:
Fracture=Bone Attack: Linking Hip Fractures to Osteoporosis Care Angela M. Cheung, MD, PhD, FRCPC Professor of Medicine, University of Toronto Potential Conflicts of Interests Industry Grants (to UHN)
More informationFragility Fractures and Secondary Fracture Prevention DeAnn Stowe, RN, MSN, ACNP-BC Cox Health- South Fracture Liaison Service
Fragility Fractures and Secondary Fracture Prevention DeAnn Stowe, RN, MSN, ACNP-BC Cox Health- South Fracture Liaison Service Objectives Define Fragility Fractures and discuss importance of identification
More informationBecause the low bone mass and deterioration
OSTEOPOROSIS A look at recent expert guidelines and key studies in bone health, the findings of which affect your patients young and old Steven R. Goldstein, MD Dr. Goldstein is Professor of Obstetrics
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationChallenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA
Challenging the Current Osteoporosis Guidelines Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Whom to screen Which test How to diagnose Whom to treat Benefits
More informationBONIVA (ibandronate sodium)
BONIVA (ibandronate sodium) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationThe Thin Bone Disease
Osteoporosis The Thin Bone Disease written by Harvard Medical School www.patientedu.org Healthy bones are amazingly strong; ounce for ounce, they can support as much weight as reinforced concrete. But
More information